Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT04522557 Completed - Breast Neoplasms Clinical Trials

Type I Interferon Alfa-2a in Postmastectomy Breast Reconstruction

Start date: August 6, 2020
Phase: Phase 1
Study type: Interventional

RATIONALE: Implant-based reconstruction have become the most popular choices of reconstruction for women undergoing breast mastectomy. Postoperative complications like infection and tumor recurrence limit its application. Interferons (IFNs) are pleiotropic cytokines that involve in immunoregulatory, anticancer and restricting infection. Especially, type I IFN signaling is reported favourable for the success of conventional chemotherapeutics, radiotherapy and immunotherapy. In addition, type I IFN can regulate the activity of almost all immune cell types (including T cells, macrophages and innate lymphocytes), creating a well-established immune environment to defense infectious and relapsing disease. Implants are rapidly coated with extracellular matrix proteins and immune protein components for the formation of a typical capsule. At the specific time point before implantation, the locally utilized of IFN in intracavity breast is assumed to modify cellular immune responses thus contributing to decreasing infection and tumor recurrence. PURPOSE: This non-randomized phase I trial aims to explore dose range of IFNα-2a. Adverse events are observed to assess drug safety and human tolerance index.

NCT ID: NCT04521764 Recruiting - Clinical trials for Anatomic Stage IV Breast Cancer AJCC v8

A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer

Start date: September 23, 2020
Phase: Phase 1
Study type: Interventional

This phase I trial investigates the side effects and best dose of using a modified measles virus, MV-s-NAP, in treating patients with invasive breast cancer that has spread to other places in the body (metastatic). Both the unmodified vaccination measles virus (MV-Edm) and this modified virus (MV-s-NAP) have been shown to multiply in and destroy breast cancer cells in the test tube and in research mice. MV-s-NAP has been altered by having an extra gene (piece of deoxyribonucleic acid [DNA]) so that virus can make a protein called helicobacter pylori neutrophil activating protein (NAP) which is normally expressed in inflammatory reactions. Monitoring blood, urine, tissue, and throat swab samples, and using imaging tests may help to determine whether MV-s-NAP has any impact on the amount of disease present in metastatic breast cancer patients.

NCT ID: NCT04518085 Completed - Breast Cancer Clinical Trials

Psychological Interventions to Prevent Late Effects in Breast Cancer

PREVENT
Start date: October 1, 2020
Phase: N/A
Study type: Interventional

The study aims to investigate whether a combined pre-operative medical hypnosis plus a post-operative internet-based acceptance and commitment intervention are more effective in preventing post-surgical pain and fatigue following breast cancer surgery compared with pre-operative mindfulness plus treatment as usual.

NCT ID: NCT04517838 Recruiting - Clinical trials for Breast Adenocarcinoma

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

Start date: July 27, 2020
Phase:
Study type: Observational

This study gathers information from the blood cells and tumor tissue during treatment with anti-HER2 therapies, such as trastuzumab, pertuzumab, lapatinib, or neratinib, in patients with HER2 positive stage I-IV breast cancer who are scheduled to start anti-HER2 therapy. The information gained from this study may help researchers better understand the relation between cell response and anti-HER2 therapies.

NCT ID: NCT04517370 Completed - Breast Cancer Clinical Trials

CO2 Laser Therapy for the Treatment of GSM in Patients With Breast Cancer

Start date: February 1, 2019
Phase: N/A
Study type: Interventional

Given the need for an effective, non-hormonal treatment for Genitourinary syndrome of menopause GSM) symptoms in breast cancer survivors, the reported efficacy of fractional CO2 laser as such a treatment in retrospective studies, the study aims to evaluate the efficacy of CO2 laser for the treatment of GSM in breast cancer patients, in a prospective, randomized, blinded, placebo-controlled trial.

NCT ID: NCT04517318 Completed - Breast Cancer Clinical Trials

Treatment After Palbociclib-containing Regimens

Start date: August 15, 2017
Phase:
Study type: Observational

To evaluate the prescription patterns and treatment outcomes of subsequent therapies after progression on palbociclib in the real world.

NCT ID: NCT04517305 Completed - Breast Cancer Clinical Trials

Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients

Start date: May 15, 2018
Phase:
Study type: Observational

To evaluate the patterns and treatment outcomes of pyrotinib plus vinorelbine in the real world.

NCT ID: NCT04517292 Not yet recruiting - Breast Cancer Clinical Trials

Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)

GEP
Start date: October 8, 2020
Phase: Phase 2
Study type: Interventional

Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)

NCT ID: NCT04517266 Recruiting - Breast Cancer Clinical Trials

Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

The effect of internal mammary irradiation (IMI) added to whole-breast or thoracic-wall irradiation plus supraclavicular (SVC) irradiation after surgery on survival among women with early-stage intermediate risk (N1) breast cancer remains debated. The present study aimed to identified patient could be omitted from internal mammary lymph node irradiation by using a clinical-genomic model.

NCT ID: NCT04516330 Completed - Clinical trials for Multicentric Breast Cancer

Can MicroRNA's Predict Multicentricity in Breast Cancer?

Start date: February 2014
Phase: N/A
Study type: Interventional

The aim of this study is to determine if microRNA's have role in predicting multicentricity in breast cancer. If a specific microRNA will be found to be related with multicentricity, it will help us to make appropriate decisions on the treatment of patients with multicentric breast cancer.